Stockreport

Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update [Seeking Alpha]

Krystal Biotech, Inc.  (KRYS) 
Last krystal biotech, inc. earnings: 11/4 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.krystalbio.com/investors
PDF A single registrational trial of KB707 plus chemotherapy versus chemotherapy alone may support regulatory filing, with interim analysis expected in H2 2026. VYJUVEK r [Read more]